MA30515B1 - Formulations lyophilisees d'anticorps anti-egfr - Google Patents

Formulations lyophilisees d'anticorps anti-egfr

Info

Publication number
MA30515B1
MA30515B1 MA31475A MA31475A MA30515B1 MA 30515 B1 MA30515 B1 MA 30515B1 MA 31475 A MA31475 A MA 31475A MA 31475 A MA31475 A MA 31475A MA 30515 B1 MA30515 B1 MA 30515B1
Authority
MA
Morocco
Prior art keywords
lyophilized formulations
egfr antibodies
provides
present
lactobionic acid
Prior art date
Application number
MA31475A
Other languages
English (en)
Inventor
Meera Agarkhed
Arvind Srivastava
Joel Goldstein
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Publication of MA30515B1 publication Critical patent/MA30515B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Dans une incarnation, la présente invention fournit une formulation lyophilisée stable comportant un anticorps anti-EGFR, de préférence cetuximab; acide lactobionic; et un tampon, de préférence histidine. Dans une incarnation préférable, la présente invention fournit une formulation lyophilisée stable comportant environ 50 mg/ml à environ 140 mg/ml d'ERBITUX®, d'environ 0.125 % acide lactobionic, de solution tampon d'histidine d'environ 25 millimolaires à un pH environ de 6.0, d'environ 0.005 % Tween 80®, et de glycine environ 1.875 %.
MA31475A 2006-06-14 2008-12-12 Formulations lyophilisees d'anticorps anti-egfr MA30515B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81395806P 2006-06-14 2006-06-14

Publications (1)

Publication Number Publication Date
MA30515B1 true MA30515B1 (fr) 2009-06-01

Family

ID=38832820

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31475A MA30515B1 (fr) 2006-06-14 2008-12-12 Formulations lyophilisees d'anticorps anti-egfr

Country Status (18)

Country Link
US (1) US20100158925A1 (fr)
EP (1) EP2029163A4 (fr)
JP (1) JP2009540015A (fr)
KR (1) KR20090021298A (fr)
CN (1) CN101466404A (fr)
AU (1) AU2007260769A1 (fr)
BR (1) BRPI0713421A2 (fr)
CA (1) CA2654794A1 (fr)
CR (1) CR10493A (fr)
EA (1) EA200870538A1 (fr)
EC (1) ECSP088962A (fr)
IL (1) IL195794A0 (fr)
MA (1) MA30515B1 (fr)
MX (1) MX2008015852A (fr)
NO (1) NO20085131L (fr)
TN (1) TNSN08511A1 (fr)
WO (1) WO2007147001A2 (fr)
ZA (1) ZA200810456B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7705132B2 (en) * 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
CN101716343A (zh) * 2008-10-09 2010-06-02 哈药集团生物工程有限公司 一种单克隆抗体的冻干制剂
FR2944448B1 (fr) * 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
PL3721904T3 (pl) * 2009-11-20 2022-01-31 Biocon Limited Formulacje przeciwciała t1h
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
US20110158987A1 (en) * 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
BR112012033457A2 (pt) * 2010-07-02 2017-04-04 Medimmune Llc formulações de anticorpo.
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
JP6693872B2 (ja) * 2013-07-25 2020-05-13 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
CN104341505A (zh) * 2013-07-29 2015-02-11 西藏海思科药业集团股份有限公司 对蒙古人种和高加索人种低免疫原性的、抗egfr的人鼠嵌合抗体
WO2015038984A2 (fr) * 2013-09-12 2015-03-19 Halozyme, Inc. Anticorps anti-récepteur du facteur de croissance épidermique modifiés et procédés pour les utiliser
WO2015185998A2 (fr) 2014-04-11 2015-12-10 Acerta Pharma B.V. Procédés de blocage de la voie de signalisation des cxcr-4/sdf-1 à l'aide d'inhibiteurs de kinase x de moelle osseuse
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
CA2955947A1 (fr) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispecifiques, anticorps anti-cd3 activables multispecifiques et procedes d'utilisation de ces anticorps
US20170231995A1 (en) 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
CA2944085C (fr) * 2014-09-16 2018-04-10 Ease Charm Limited Anticorps anti-egfr et leurs utilisations
CN105435221B (zh) * 2014-09-22 2021-09-28 正大天晴药业集团股份有限公司 一种针对血管内皮生长因子的人源化抗体的药物组合物
WO2016055982A1 (fr) 2014-10-10 2016-04-14 Acerta Pharma B.V. Composés quinoléine et quinazoline
WO2016087994A1 (fr) 2014-12-05 2016-06-09 Acerta Pharma B.V. Inhibiteurs de btk pour le traitement de tumeurs solides par modulation du micro-environnement tumoral
US10717783B2 (en) * 2014-12-22 2020-07-21 Zeren Gao Bispecific tetravalent antibodies and methods of making and using thereof
US12428483B2 (en) 2014-12-22 2025-09-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
KR101776879B1 (ko) * 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
WO2017077507A1 (fr) 2015-11-06 2017-05-11 Acerta Pharma B.V. Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
MX2019007824A (es) * 2016-12-28 2019-09-09 Japan Chem Res Preparacion liofilizada.
BR112019021723A2 (pt) * 2017-04-18 2021-06-29 Dr. Reddy's Laboratories Limited formulação de anticorpo líquida estável, anticorpo na formulação, formulação líquida estável de anticorpo anti-il6r, formulação líquida estável de tocilizumab em sistema de tampão de fosfato-aminoácido, e, formulação líquida estável de tocilizumab
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
WO2019232478A1 (fr) 2018-06-01 2019-12-05 Rakuten Medical, Inc. Compositions de conjugué de colorant à la phtalocyanine
CN110960490A (zh) * 2018-09-28 2020-04-07 江苏恒瑞医药股份有限公司 一种抗egfr抗体偶联药物组合物及其用途
JP7542543B2 (ja) 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
US12704501B2 (en) 2019-03-29 2026-08-11 Rakuten Medical, Inc. Methods for photoimmunotherapy and related biomarkers
JP2022545312A (ja) 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
CA3142710A1 (fr) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions et procedes de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoide
US20230220105A1 (en) * 2019-06-06 2023-07-13 Janux Therapeutics, Inc. Tumor activated t cell engagers and methods of use thereof
CU20190104A7 (es) * 2019-12-17 2021-08-06 Ct Inmunologia Molecular Formulación estable del anticuerpo nimotuzumab
AU2021326469C1 (en) 2020-08-11 2026-04-30 Janux Therapeutics, Inc. Cleavable linker compositions and methods
EP4259193A4 (fr) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions et méthodes associées à des anticorps activés par des tumeurs ciblant psma et des antigènes de cellules effectrices
EP4259200A1 (fr) * 2020-12-11 2023-10-18 Boehringer Ingelheim International GmbH Formulation pour application polyvalente
AU2022357570A1 (en) * 2021-10-03 2024-04-11 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof
CN119855620A (zh) * 2022-09-16 2025-04-18 国立研究开发法人量子科学技术研究开发机构 放射性医药组合物的中间体的制造方法、放射性医药组合物的中间体的纯化用试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62158160A (ja) * 1985-12-27 1987-07-14 堺化学工業株式会社 成形触媒及び接触反応方法
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6695940B2 (en) * 2001-04-05 2004-02-24 Alan D. Devoe Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
ES2387809T3 (es) * 2004-03-19 2012-10-02 Imclone Llc Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
WO2007095337A2 (fr) * 2006-02-15 2007-08-23 Imclone Systems Incorporated formulation d'anticorps

Also Published As

Publication number Publication date
EP2029163A2 (fr) 2009-03-04
TNSN08511A1 (en) 2010-04-14
AU2007260769A1 (en) 2007-12-21
NO20085131L (no) 2009-03-13
KR20090021298A (ko) 2009-03-02
EA200870538A1 (ru) 2009-04-28
US20100158925A1 (en) 2010-06-24
ECSP088962A (es) 2009-01-30
CR10493A (es) 2009-02-26
BRPI0713421A2 (pt) 2012-03-13
CN101466404A (zh) 2009-06-24
EP2029163A4 (fr) 2010-08-11
JP2009540015A (ja) 2009-11-19
CA2654794A1 (fr) 2007-12-21
WO2007147001A3 (fr) 2008-07-10
MX2008015852A (es) 2009-02-23
WO2007147001A2 (fr) 2007-12-21
IL195794A0 (en) 2011-08-01
ZA200810456B (en) 2009-12-30

Similar Documents

Publication Publication Date Title
TNSN08511A1 (en) Lyophilized formulations of anti-egfr antibodies
NZ595526A (en) Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
CO5660273A2 (es) Formulaciones de proteina y anticuerpo de alta concentracion
EP1855719A4 (fr) Neutralisation d'anticorps monoclonaux contre le coronavirus associe au syndrome respiratoire aigu severe
CO6251275A2 (es) Formulaciones de inmunoglobulina liofilizadas y metodos para su preparacion
NZ596367A (en) Lyophilized therapeutic peptibody formulations
NZ613809A (en) Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
HRP20230462T1 (hr) Supkutana formulacija protutijela anti-her2
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
HRP20120893T1 (hr) Formulacija protutijela na histidin-acetatnom puferu
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
RU2004122632A (ru) Лиофилизированный препарат, содержащий антитела против рецептора egf
EP4233892A3 (fr) Formulation stable anti-ifnar1
NZ629261A (en) Pharmaceutical formulations of tnf-alpha antibodies
PE20171512A1 (es) Anticuerpos anti-fap
EP1531862A4 (fr) Preparations d'anticorps anti-vrs liquides stabilisees
EA201000424A1 (ru) Антитела к il-23
PE20140220A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
MA35355B1 (fr) Formulations stabilisées contenant des anticorps anti-pcsk9
MA30470B1 (fr) Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste.
PE20141159A1 (es) Metodos para tratar o prevenir trastornos relacionados con el colesterol
CR8932A (es) Composicion de anticuerpo her2
MA33757B1 (fr) Protéines de liaison à l'antigène de l'il-23 humaine
RU2009148286A (ru) Жидкая фармацевтическая композиция ботулинического токсина
HRP20060033B1 (hr) Humana anti-ngf neutralizirajuä†a antitijela kao selektivni inhibitori ngf rute